Cost-effectiveness of metformin in the prevention of Type 2 diabetes mellitus: A systematic review

Nguyen Thi Thu Thuy; To Hue Nghi; Tran Ngoc Thien Thanh; Huynh Hai Duong; Nguyen Cao Duc Huy

doi:10.59294/HIUJS.VOL.7.2024.690

Từ khóa:

systematic review, cost-effectiveness, metformin, prediabetes

Tóm tắt

Background and aims: Type 2 diabetes mellitus (T2DM) is a common metabolic disorder with serious complications. Prediabetes treatment with metformin or lifestyle changes has been shown to delay the progression of prediabetes to T2DM, thus alleviating the overall economic burden associated with T2DM. This systematic review was conducted to evaluate the cost-effectiveness of metformin in the treatment of prediabetes. Methods and results: A PRISMA-guided systematic review was performed on databases: Pubmed, Cochrane, and Embase with appropriate keywords and phrases. CHEERS checklist was used to evaluate the studies' quality. Research characteristics and outcomes were examined, and Incremental cost-effective ratio (ICER) was converted to the USD 2020. With 402 articles identified through the search strategies, 16 articles that met the selection criteria were included for analysis in this review. All articles were deemed to be of relatively good quality according to CHEERS checklist. These analyses were conducted in developed countries from different perspectives and time frames. One of 16 studies revealed metformin as cost-saving compared to placebo, while the remaining studies reported metformin to be cost-effective compared to placebo, no intervention, or standard care, with ICERs below the willingness-to-pay threshold (ranging from $457/QALY to $164,621/QALY). However, conclusions regarding the cost-effectiveness of metformin versus lifestyle changes varied depending on different perspectives and program intensity. Conclusion: Metformin was dominant or cost-effective compared to placebo and no interventions in the treatment of prediabetes. However, the question about cost-effectiveness of metformin versus lifestyle change remained a subject of controversy among the studies. Further investigation into the cost-effectiveness of metformin compared to lifestyle change was recommended, particularly in developing countries where there is a high prevalence rate and limited healthcare resources.

Abstract

Background and aims: Type 2 diabetes mellitus (T2DM) is a common metabolic disorder with serious complications. Prediabetes treatment with metformin or lifestyle changes has been shown to delay the progression of prediabetes to T2DM, thus alleviating the overall economic burden associated with T2DM. This systematic review was conducted to evaluate the cost-effectiveness of metformin in the treatment of prediabetes. Methods and results: A PRISMA-guided systematic review was performed on databases: Pubmed, Cochrane, and Embase with appropriate keywords and phrases. CHEERS checklist was used to evaluate the studies' quality. Research characteristics and outcomes were examined, and Incremental cost-effective ratio (ICER) was converted to the USD 2020. With 402 articles identified through the search strategies, 16 articles that met the selection criteria were included for analysis in this review. All articles were deemed to be of relatively good quality according to CHEERS checklist. These analyses were conducted in developed countries from different perspectives and time frames. One of 16 studies revealed metformin as cost-saving compared to placebo, while the remaining studies reported metformin to be cost-effective compared to placebo, no intervention, or standard care, with ICERs below the willingness-to-pay threshold (ranging from $457/QALY to $164,621/QALY). However, conclusions regarding the cost-effectiveness of metformin versus lifestyle changes varied depending on different perspectives and program intensity. Conclusion: Metformin was dominant or cost-effective compared to placebo and no interventions in the treatment of prediabetes. However, the question about cost-effectiveness of metformin versus lifestyle change remained a subject of controversy among the studies. Further investigation into the cost-effectiveness of metformin compared to lifestyle change was recommended, particularly in developing countries where there is a high prevalence rate and limited healthcare resources.

Tài liệu tham khảo

[1] A. G. Tabák, C. Herder,… and M. J. T. L. Kivimäki, "Prediabetes: A high-risk state for diabetes development," Lencet, vol. 379, no. 9833, pp. 2279-2290, 2012.

DOI: https://doi.org/10.1016/S0140-6736(12)60283-9

[2] U. J. C. d. Hostalek and endocrinology, "Global epidemiology of prediabetes-present and future perspectives," Clin Diabetes Endocrinol, vol. 5, no. 1, pp. 1-5, 2019.

DOI: https://doi.org/10.1186/s40842-019-0080-0

[3] I. D. Federation. (2019, 12/09). IDF Diabetes Atlas 9th edition. Available: https://www.diabete-satlas.org/en/

[4] W. C. Knowler et al., "10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study," (in eng), Lancet, vol. 374, no. 9702, pp. 1677-86, Nov 14 2009.

DOI: https://doi.org/10.1016/S0140-6736(09)61457-4

[5] D. Husereau et al., "Consolidated health economic evaluation reporting standards (CHEERS) explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force," vol. 16, no. 2, pp. 231-250, 2013.
[6] The World Bank Group: Consumer Price Index, 2021. Available: https://data.worldbank.org
/indicator/fp.cpi.totl

DOI: https://doi.org/10.1016/j.jval.2013.02.002

[7] D. M. Eddy, L. Schlessinger and R. Kahn, "Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes," (in eng), Ann Intern Med, vol. 143, no. 4, pp. 251- 64, Aug 16 2005.

DOI: https://doi.org/10.7326/0003-4819-143-4-200508160-00006

[8] PMCID: PMC1360736, "Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes," (in eng), Diabetes Care, vol. 26, no. 9, pp. 2518-23, Sep 2003.

DOI: https://doi.org/10.2337/diacare.26.9.2518

[9] A. J. Palmer, S. Roze, W. J. Valentine,… and P. Z. Zimmet, "Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom," (in eng), Clin Ther, vol. 26, no. 2, pp. 304-21, Feb 2004.

DOI: https://doi.org/10.1016/S0149-2918(04)90029-X

[10] J. J. Caro, D. Getsios, I. Caro,… and J. A. O'Brien, "Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada," (in eng), Diabet Med, vol. 21, no. 11, pp. 1229-36, Nov 2004.

DOI: https://doi.org/10.1111/j.1464-5491.2004.01330.x

[11] W. H. Herman et al., "The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance," (in eng), Ann Intern Med, vol. 142, no. 5, pp. 323-32, Mar 1 2005.

DOI: https://doi.org/10.7326/0003-4819-142-5-200503010-00007

[12] A. Icks et al., "Clinical and cost‐effectiveness of primary prevention of Type 2 diabetes in a 'real world'routine healthcare setting: model based on the KORA Survey 2000," vol. 24, no. 5, pp. 473- 480, 2007.

DOI: https://doi.org/10.1111/j.1464-5491.2007.02108.x

[13] A. Ramachandran, C. Snehalatha,… and Z. Ping, "Cost-effectiveness of the interventions in the primary prevention of diabetes among asian indians: within-trial results of the indian diabetes prevention programme (IDPP)," (in eng), Diabetes Care, vol. 30, no. 10, pp. 2548-52, Oct 2007.

DOI: https://doi.org/10.2337/dc07-0150

[14] M. Y. Bertram, S. S. Lim,… and T. Vos, "Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care," (in eng), Diabetologia, vol. 53, no. 5, pp. 875-81, May 2010.

DOI: https://doi.org/10.1007/s00125-010-1661-8

[15] T. M. Schaufler and M. Wolff, "Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany," (in eng), Appl Health Econ Health Policy, vol. 8, no. 3, pp. 191- 202, 2010.

DOI: https://doi.org/10.2165/11532880-000000000-00000

[16] A. J. Palmer and D. M. Tucker, "Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis," (in eng), Prim Care Diabetes, vol. 6, no. 2, pp. 109-21, Jul 2012.

DOI: https://doi.org/10.1016/j.pcd.2011.10.006

[17] T. D. P. P. R. Group, "The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS," (in eng), Diabetes Care, vol. 35, no. 4, pp. 723-30, Apr 2012.

DOI: https://doi.org/10.2337/dc11-1468

[18] W. H. Herman et al., "Effectiveness and cost-effectiveness of diabetes prevention among adherent participants," (in eng), Am J Manag Care, vol. 19, no. 3, pp. 194-202, 2013.

[19] M. E. Png and J. S. Yoong, "Evaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore," (in eng), PLoS One, vol. 9, no. 9, p. e107225, 2014.

DOI: https://doi.org/10.1371/journal.pone.0107225

[20] S. Roberts, D. Craig, A. Adler, K. McPherson, and T. Greenhalgh, "Economic evaluation of type 2 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia," (in eng), BMC Med, vol. 16, no. 1, p. 16, Jan 30 2018.

DOI: https://doi.org/10.1186/s12916-017-0984-4

[21] D. Islek et al., "Cost-effectiveness of a stepwise approach vs standard care for diabetes prevention in india," (in eng), JAMA Netw Open, vol. 3, no. 7, p. e207539, Jul 1 2020.

DOI: https://doi.org/10.1001/jamanetworkopen.2020.7539

[22] D. J. T. E. J. o. H. E. Vandenberghe, "Simulating lifestyle and medical interventions to prevent type-2 diabetes: an economic evaluation for Belgium," pp. 1-12, 2021.

[23] N. Cho et al., "IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045," vol. 138, pp. 271-281, 2018.

DOI: https://doi.org/10.1016/j.diabres.2018.02.023

[24] W. C. Knowler et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin," (in eng), N Engl J Med, vol. 346, no. 6, pp. 393-403, Feb 7 2002.

DOI: https://doi.org/10.1056/NEJMoa012512

[25] G. Li et al., "Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the da qing diabetes prevention study: a 23-year follow-up study," (in eng), Lancet Diabetes Endocrinol, vol. 2, no. 6, pp. 474-80, Jun 2014.

DOI: https://doi.org/10.1016/S2213-8587(14)70057-9

[26] T. Moin et al., "Review of metformin use for type 2 diabetes prevention," (in eng), Am J Prev Med, vol. 55, no. 4, pp. 565-574, Oct 2018.

DOI: https://doi.org/10.1016/j.amepre.2018.04.038

[27] S. Roberts, E. Barry, D. Craig,… and T. Greenhalgh, "Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes," (in eng), BMJ Open, vol. 7, no. 11, p. e017184, Nov 15 2017.

DOI: https://doi.org/10.1136/bmjopen-2017-017184

[28] S. B. Gebregergish et al., "The cost-effectiveness of metformin in pre-diabetics: a systematic literature review of health economic evaluations," vol. 20, no. 2, pp. 207-219, 2020.

DOI: https://doi.org/10.1080/14737167.2020.1688146